1
|
Giancotti G, Nannetti G, Padalino G, Landini M, Santos-Ferreira N, Van Dycke J, Naccarato V, Patel U, Silvestri R, Neyts J, Gozalbo-Rovira R, Rodríguez-Díaz J, Rocha-Pereira J, Brancale A, Ferla S, Bassetto M. Structural Investigations on Novel Non-Nucleoside Inhibitors of Human Norovirus Polymerase. Viruses 2022; 15:74. [PMID: 36680114 PMCID: PMC9864251 DOI: 10.3390/v15010074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2022] [Revised: 12/20/2022] [Accepted: 12/21/2022] [Indexed: 12/29/2022] Open
Abstract
Human norovirus is the first cause of foodborne disease worldwide, leading to extensive outbreaks of acute gastroenteritis, and causing around 200,000 children to die annually in developing countries. No specific vaccines or antiviral agents are currently available, with therapeutic options limited to supportive care to prevent dehydration. The infection can become severe and lead to life-threatening complications in young children, the elderly and immunocompromised individuals, leading to a clear need for antiviral agents, to be used as treatments and as prophylactic measures in case of outbreaks. Due to the key role played by the viral RNA-dependent RNA polymerase (RdRp) in the virus life cycle, this enzyme is a promising target for antiviral drug discovery. In previous studies, following in silico investigations, we identified different small-molecule inhibitors of this enzyme. In this study, we rationally modified five identified scaffolds, to further explore structure-activity relationships, and to enhance binding to the RdRp. The newly designed compounds were synthesized according to multiple-step synthetic routes and evaluated for their inhibition of the enzyme in vitro. New inhibitors with low micromolar inhibitory activity of the RdRp were identified, which provide a promising basis for further hit-to-lead optimization.
Collapse
Affiliation(s)
- Gilda Giancotti
- School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff CF10 3NB, UK
| | - Giulio Nannetti
- Medical School, Faculty of Medicine, Health and Life Science, Swansea University, Swansea SA2 8PP, UK
| | - Gilda Padalino
- School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff CF10 3NB, UK
| | - Martina Landini
- School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff CF10 3NB, UK
| | - Nanci Santos-Ferreira
- KU Leuven—Rega Institute, Department of Microbiology, Immunology and Transplantation, 3000 Leuven, Belgium
| | - Jana Van Dycke
- KU Leuven—Rega Institute, Department of Microbiology, Immunology and Transplantation, 3000 Leuven, Belgium
| | - Valentina Naccarato
- Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy
| | - Usheer Patel
- School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff CF10 3NB, UK
| | - Romano Silvestri
- Department of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy
| | - Johan Neyts
- KU Leuven—Rega Institute, Department of Microbiology, Immunology and Transplantation, 3000 Leuven, Belgium
| | - Roberto Gozalbo-Rovira
- Department of Microbiology, School of Medicine, University of Valencia, 46010 Valencia, Spain
| | - Jésus Rodríguez-Díaz
- Department of Microbiology, School of Medicine, University of Valencia, 46010 Valencia, Spain
| | - Joana Rocha-Pereira
- KU Leuven—Rega Institute, Department of Microbiology, Immunology and Transplantation, 3000 Leuven, Belgium
| | - Andrea Brancale
- School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff CF10 3NB, UK
- Vysoká Škola Chemiko-Technologiká v Praze, 165 00 Prague, Czech Republic
| | - Salvatore Ferla
- Medical School, Faculty of Medicine, Health and Life Science, Swansea University, Swansea SA2 8PP, UK
| | - Marcella Bassetto
- Department of Chemistry, College of Science and Engineering, Swansea University, Swansea SA2 8PP, UK
| |
Collapse
|
2
|
Massari S, Bertagnin C, Pismataro MC, Donnadio A, Nannetti G, Felicetti T, Di Bona S, Nizi MG, Tensi L, Manfroni G, Loza MI, Sabatini S, Cecchetti V, Brea J, Goracci L, Loregian A, Tabarrini O. Synthesis and characterization of 1,2,4-triazolo[1,5-a]pyrimidine-2-carboxamide-based compounds targeting the PA-PB1 interface of influenza A virus polymerase. Eur J Med Chem 2020; 209:112944. [PMID: 33328103 PMCID: PMC7561591 DOI: 10.1016/j.ejmech.2020.112944] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2020] [Revised: 10/13/2020] [Accepted: 10/13/2020] [Indexed: 01/06/2023]
Abstract
Influenza viruses (Flu) are responsible for seasonal epidemics causing high rates of morbidity, which can dramatically increase during severe pandemic outbreaks. Antiviral drugs are an indispensable weapon to treat infected people and reduce the impact on human health, nevertheless anti-Flu armamentarium still remains inadequate. In search for new anti-Flu drugs, our group has focused on viral RNA-dependent RNA polymerase (RdRP) developing disruptors of PA-PB1 subunits interface with the best compounds characterized by cycloheptathiophene-3-carboxamide and 1,2,4-triazolo[1,5-a]pyrimidine-2-carboxamide scaffolds. By merging these moieties, two very interesting hybrid compounds were recently identified, starting from which, in this paper, a series of analogues were designed and synthesized. In particular, a thorough exploration of the cycloheptathiophene-3-carboxamide moiety led to acquire important SAR insight and identify new active compounds showing both the ability to inhibit PA-PB1 interaction and viral replication in the micromolar range and at non-toxic concentrations. For few compounds, the ability to efficiently inhibit PA-PB1 subunits interaction did not translate into anti-Flu activity. Chemical/physical properties were investigated for a couple of compounds suggesting that the low solubility of compound 14, due to a strong crystal lattice, may have impaired its antiviral activity. Finally, computational studies performed on compound 23, in which the phenyl ring suitably replaced the cycloheptathiophene, suggested that, in addition to hydrophobic interactions, H-bonds enhanced its binding within the PAC cavity.
Collapse
Affiliation(s)
- Serena Massari
- Department of Pharmaceutical Sciences, University of Perugia, 06123, Perugia, Italy.
| | - Chiara Bertagnin
- Department of Molecular Medicine, University of Padua, 35121, Padua, Italy
| | | | - Anna Donnadio
- Department of Pharmaceutical Sciences, University of Perugia, 06123, Perugia, Italy
| | - Giulio Nannetti
- Department of Molecular Medicine, University of Padua, 35121, Padua, Italy
| | - Tommaso Felicetti
- Department of Pharmaceutical Sciences, University of Perugia, 06123, Perugia, Italy
| | - Stefano Di Bona
- Department of Chemistry, Biology and Biotechnology, University of Perugia, 06123, Perugia, Italy
| | - Maria Giulia Nizi
- Department of Pharmaceutical Sciences, University of Perugia, 06123, Perugia, Italy
| | - Leonardo Tensi
- Department of Chemistry, Biology and Biotechnology, University of Perugia, 06123, Perugia, Italy
| | - Giuseppe Manfroni
- Department of Pharmaceutical Sciences, University of Perugia, 06123, Perugia, Italy
| | - Maria Isabel Loza
- CIMUS Research Center, University of Santiago de Compostela, 15782, Santiago de Compostela, Spain
| | - Stefano Sabatini
- Department of Pharmaceutical Sciences, University of Perugia, 06123, Perugia, Italy
| | - Violetta Cecchetti
- Department of Pharmaceutical Sciences, University of Perugia, 06123, Perugia, Italy
| | - Jose Brea
- CIMUS Research Center, University of Santiago de Compostela, 15782, Santiago de Compostela, Spain
| | - Laura Goracci
- Department of Chemistry, Biology and Biotechnology, University of Perugia, 06123, Perugia, Italy
| | - Arianna Loregian
- Department of Molecular Medicine, University of Padua, 35121, Padua, Italy
| | - Oriana Tabarrini
- Department of Pharmaceutical Sciences, University of Perugia, 06123, Perugia, Italy
| |
Collapse
|
3
|
Nannetti G, Massari S, Mercorelli B, Bertagnin C, Desantis J, Palù G, Tabarrini O, Loregian A. Potent and broad-spectrum cycloheptathiophene-3-carboxamide compounds that target the PA-PB1 interaction of influenza virus RNA polymerase and possess a high barrier to drug resistance. Antiviral Res 2019; 165:55-64. [PMID: 30885750 DOI: 10.1016/j.antiviral.2019.03.003] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2018] [Revised: 02/25/2019] [Accepted: 03/04/2019] [Indexed: 12/17/2022]
Abstract
Influenza viruses are major respiratory pathogens responsible for both seasonal epidemics and occasional pandemics worldwide. The current available treatment options have limited efficacy and thus the development of new antivirals is highly needed. We previously reported the identification of a series of cycloheptathiophene-3-carboxamide compounds as influenza A virus inhibitors that act by targeting the protein-protein interactions between the PA-PB1 subunits of the viral polymerase. In this study, we characterized the antiviral properties of the most promising compounds as well as investigated their propensity to induce drug resistance. Our results show that some of the selected compounds possess potent, broad-spectrum anti-influenza activity as they efficiently inhibited the replication of several strains of influenza A and B viruses, including an oseltamivir-resistant clinical isolate, with nanomolar or low-micromolar potency. The most promising compounds specifically inhibited the PA-PB1 binding in vitro and interfered with the influenza A virus polymerase activity in a cellular context, without showing cytotoxicity. The most active PA-PB1 inhibitors showed to possess a drug resistance barrier higher than that of oseltamivir. Indeed, no viral variants with reduced susceptibility to the selected compounds emerged after serial passages of influenza A virus under drug selective pressure. Overall, our studies identified potent PA-PB1 inhibitors as promising candidates for the development of new anti-influenza drugs.
Collapse
Affiliation(s)
- Giulio Nannetti
- Department of Molecular Medicine, University of Padua, Padua, Italy
| | - Serena Massari
- Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy
| | | | - Chiara Bertagnin
- Department of Molecular Medicine, University of Padua, Padua, Italy
| | - Jenny Desantis
- Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy
| | - Giorgio Palù
- Department of Molecular Medicine, University of Padua, Padua, Italy
| | - Oriana Tabarrini
- Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy
| | - Arianna Loregian
- Department of Molecular Medicine, University of Padua, Padua, Italy.
| |
Collapse
|
4
|
Nannetti G, Pagni S, Palù G, Loregian A. A sensitive and validated HPLC-UV method for the quantitative determination of the new antifungal drug isavuconazole in human plasma. Biomed Chromatogr 2018; 32:e4333. [PMID: 29978912 DOI: 10.1002/bmc.4333] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2017] [Revised: 06/21/2018] [Accepted: 06/29/2018] [Indexed: 01/07/2023]
Abstract
Isavuconazole is a broad-spectrum triazole antifungal drug recently approved for the therapy of both invasive aspergillosis and mucormycosis. To support a widespread therapeutic drug monitoring of isavuconazole, a simple, sensitive, and precise high-performance liquid chromatography method with UV detection was developed and fully validated for the quantification of this drug in human plasma. The method involved a combined protein precipitation-solid-phase extraction and a chromatographic separation on a Waters XTerra RP18 (150 × 4.6 mm, 3.5 μm) column using an isocratic mobile phase of ammonium acetate buffer (pH 8.0, 10 mm) and acetonitrile (45:55, v/v). The UV detection was performed at 285 nm. This method was linear (correlation coefficients ≥0.998), specific (no interference with plasma components or various potentially co-administrated drugs), sensitive (lower limit of quantification of 0.025 μg/mL), reproducible (coefficients of variation were ≤7.9%) and accurate (deviations ranged from -5.0 to 8.0%) over the range of 0.025-10 μg/mL. The method fulfilled all of the US Food and Drug Administration guidelines validation criteria and performed well in an international proficiency testing program. The assay was also successfully applied to routine therapeutic drug monitoring of patients and to drug stability investigations under various conditions.
Collapse
Affiliation(s)
- Giulio Nannetti
- Department of Molecular Medicine, University of Padua, Padua, Italy
| | - Silvana Pagni
- Department of Molecular Medicine, University of Padua, Padua, Italy.,Clinical Microbiology and Virology Unit, Padua University Hospital, Padua, Italy
| | - Giorgio Palù
- Department of Molecular Medicine, University of Padua, Padua, Italy.,Clinical Microbiology and Virology Unit, Padua University Hospital, Padua, Italy
| | - Arianna Loregian
- Department of Molecular Medicine, University of Padua, Padua, Italy.,Clinical Microbiology and Virology Unit, Padua University Hospital, Padua, Italy
| |
Collapse
|
5
|
Desantis J, Nannetti G, Massari S, Barreca ML, Manfroni G, Cecchetti V, Palù G, Goracci L, Loregian A, Tabarrini O. Corrigendum to "Exploring the cycloheptathiophene-3-carboxamide scaffold to disrupt the interactions of the influenza polymerase subunits and obtain potent anti-influenza activity" [Eur. J. Med. Chem. 138 (2017) 128-139]. Eur J Med Chem 2018; 156:302-303. [PMID: 30007243 DOI: 10.1016/j.ejmech.2018.07.009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- Jenny Desantis
- Department of Pharmaceutical Sciences, University of Perugia, 06123, Perugia, Italy
| | - Giulio Nannetti
- Department of Molecular Medicine, University of Padua, 35121, Padua, Italy
| | - Serena Massari
- Department of Pharmaceutical Sciences, University of Perugia, 06123, Perugia, Italy
| | | | - Giuseppe Manfroni
- Department of Pharmaceutical Sciences, University of Perugia, 06123, Perugia, Italy
| | - Violetta Cecchetti
- Department of Pharmaceutical Sciences, University of Perugia, 06123, Perugia, Italy
| | - Giorgio Palù
- Department of Molecular Medicine, University of Padua, 35121, Padua, Italy
| | - Laura Goracci
- Department of Chemistry, Biology and Biotechnology, University of Perugia, 06123, Perugia, Italy.
| | - Arianna Loregian
- Department of Molecular Medicine, University of Padua, 35121, Padua, Italy.
| | - Oriana Tabarrini
- Department of Pharmaceutical Sciences, University of Perugia, 06123, Perugia, Italy.
| |
Collapse
|
6
|
Desantis J, Nannetti G, Massari S, Barreca ML, Manfroni G, Cecchetti V, Palù G, Goracci L, Loregian A, Tabarrini O. Exploring the cycloheptathiophene-3-carboxamide scaffold to disrupt the interactions of the influenza polymerase subunits and obtain potent anti-influenza activity. Eur J Med Chem 2017; 138:128-139. [PMID: 28666191 DOI: 10.1016/j.ejmech.2017.06.015] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2016] [Revised: 04/13/2017] [Accepted: 06/07/2017] [Indexed: 11/19/2022]
Abstract
With the aim to identify small molecules able to disrupt PA-PB1 subunits interaction of influenza virus (flu) RNA-dependent RNA polymerase, and based on previous structural and computational information, in this paper we have designed and synthesized a new series of cycloheptathiophene-3-carboxamide (cHTC) derivatives. Their biological evaluation led to highlight important structural insights along with new interesting compounds, such as the 2-hydroxybenzamido derivatives 29, 31, and 32, and the 4-aminophenyl derivative 54, which inhibited viral growth in the low micromolar range (EC50 = 0.18-1.2 μM) at no toxic concentrations (CC50 > 250 μM). This study permitted to obtain among the most potent anti-flu compounds within the PA-PB1 interaction inhibitors, confirming the cHTC scaffold as particularly suitable to achieve innovative anti-flu agents.
Collapse
Affiliation(s)
- Jenny Desantis
- Department of Pharmaceutical Sciences, University of Perugia, 06123 Perugia, Italy
| | - Giulio Nannetti
- Department of Molecular Medicine, University of Padua, 35121 Padua, Italy
| | - Serena Massari
- Department of Pharmaceutical Sciences, University of Perugia, 06123 Perugia, Italy
| | | | - Giuseppe Manfroni
- Department of Pharmaceutical Sciences, University of Perugia, 06123 Perugia, Italy
| | - Violetta Cecchetti
- Department of Pharmaceutical Sciences, University of Perugia, 06123 Perugia, Italy
| | - Giorgio Palù
- Department of Molecular Medicine, University of Padua, 35121 Padua, Italy
| | - Laura Goracci
- Department of Chemistry, Biology and Biotechnology, University of Perugia, 06123 Perugia, Italy.
| | - Arianna Loregian
- Department of Molecular Medicine, University of Padua, 35121 Padua, Italy.
| | - Oriana Tabarrini
- Department of Pharmaceutical Sciences, University of Perugia, 06123 Perugia, Italy.
| |
Collapse
|
7
|
Nannetti G, Messa L, Celegato M, Pagni S, Basso M, Parisi SG, Palù G, Loregian A. Development and validation of a simple and robust HPLC method with UV detection for quantification of the hepatitis C virus inhibitor daclatasvir in human plasma. J Pharm Biomed Anal 2017; 134:275-281. [DOI: 10.1016/j.jpba.2016.11.032] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2016] [Revised: 11/07/2016] [Accepted: 11/13/2016] [Indexed: 11/16/2022]
|
8
|
Massari S, Desantis J, Nannetti G, Sabatini S, Tortorella S, Goracci L, Cecchetti V, Loregian A, Tabarrini O. Efficient and regioselective one-step synthesis of 7-aryl-5-methyl- and 5-aryl-7-methyl-2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivatives. Org Biomol Chem 2017; 15:7944-7955. [DOI: 10.1039/c7ob02085f] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Two facile and efficient one-step procedures for the regioselective synthesis of 7-aryl-5-methyl- and 5-aryl-7-methyl-2-amino-[1,2,4]triazolo[1,5-a]pyrimidines.
Collapse
Affiliation(s)
- Serena Massari
- Department of Pharmaceutical Sciences
- University of Perugia
- 06123 Perugia
- Italy
| | - Jenny Desantis
- Department of Pharmaceutical Sciences
- University of Perugia
- 06123 Perugia
- Italy
| | - Giulio Nannetti
- Department of Molecular Medicine
- University of Padua
- 35121 Padua
- Italy
| | - Stefano Sabatini
- Department of Pharmaceutical Sciences
- University of Perugia
- 06123 Perugia
- Italy
| | - Sara Tortorella
- Department of Chemistry
- Biology and Biotechnology
- University of Perugia
- 06123 Perugia
- Italy
| | - Laura Goracci
- Department of Chemistry
- Biology and Biotechnology
- University of Perugia
- 06123 Perugia
- Italy
| | - Violetta Cecchetti
- Department of Pharmaceutical Sciences
- University of Perugia
- 06123 Perugia
- Italy
| | - Arianna Loregian
- Department of Molecular Medicine
- University of Padua
- 35121 Padua
- Italy
| | - Oriana Tabarrini
- Department of Pharmaceutical Sciences
- University of Perugia
- 06123 Perugia
- Italy
| |
Collapse
|
9
|
Basařová P, Váchová T, Moore G, Nannetti G, Pišlová J. Bubble adhesion onto the hydrophobic surface in solutions of non-ionic surface-active agents. Colloids Surf A Physicochem Eng Asp 2016. [DOI: 10.1016/j.colsurfa.2015.11.069] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
10
|
Parisi SG, Loregian A, Andreis S, Nannetti G, Cavinato S, Basso M, Scaggiante R, Dal Bello F, Messa L, Cattelan AM, Palù G. Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin. Int J Infect Dis 2016; 49:151-3. [PMID: 27378577 DOI: 10.1016/j.ijid.2016.06.020] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2016] [Revised: 06/12/2016] [Accepted: 06/28/2016] [Indexed: 12/16/2022] Open
Abstract
OBJECTIVES Effective treatment with direct-acting antiviral drugs against hepatitis C virus (HCV) is a medical need in cirrhotic HIV-HCV co-infected patients. METHODS This study investigated the plasma levels of daclatasvir (DCV) and ribavirin (RBV) in HIV-HCV co-infected subjects treated with DCV, sofosbuvir, and RBV. Drug concentrations were quantified using validated high-performance liquid chromatography methods with ultraviolet detection. The HCV non-structural protein 5A and non-structural protein 5B coding regions were analyzed by population-based sequencing. RESULTS DCV was dosed at week 4 and at week 8 of treatment, and RBV at week 8. One patient had the lowest DCV level, corresponding to 32.7% of the overall median value of the other patients at week 4 and about 40% at week 8. The Y93H variant was detected in this subject at weeks 8, 16, and 20 of treatment, but not before treatment or at day 2, and the patient experienced virological failure. Another subject with the Y93H variant at baseline and appropriate DCV levels had HCV RNA <12 IU/ml at week 12 and undetectable at week 16. CONCLUSIONS Sub-optimal DCV drug levels allow the selection of resistance-associated variants and fail to contribute to antiviral activity. No definite reason for the low DCV level was found. Quantifying the drug is suggested in difficult-to-treat patients.
Collapse
Affiliation(s)
- Saverio G Parisi
- Department of Molecular Medicine, University of Padova, Via Gabelli 63, 35100 Padova, Italy.
| | - Arianna Loregian
- Department of Molecular Medicine, University of Padova, Via Gabelli 63, 35100 Padova, Italy
| | - Samantha Andreis
- Department of Molecular Medicine, University of Padova, Via Gabelli 63, 35100 Padova, Italy
| | - Giulio Nannetti
- Department of Molecular Medicine, University of Padova, Via Gabelli 63, 35100 Padova, Italy
| | | | - Monica Basso
- Department of Molecular Medicine, University of Padova, Via Gabelli 63, 35100 Padova, Italy
| | | | - Federico Dal Bello
- Department of Molecular Medicine, University of Padova, Via Gabelli 63, 35100 Padova, Italy
| | - Lorenzo Messa
- Department of Molecular Medicine, University of Padova, Via Gabelli 63, 35100 Padova, Italy
| | | | - Giorgio Palù
- Department of Molecular Medicine, University of Padova, Via Gabelli 63, 35100 Padova, Italy
| |
Collapse
|
11
|
Trist IML, Nannetti G, Tintori C, Fallacara AL, Deodato D, Mercorelli B, Palù G, Wijtmans M, Gospodova T, Edink E, Verheij M, de Esch I, Viteva L, Loregian A, Botta M. 4,6-Diphenylpyridines as Promising Novel Anti-Influenza Agents Targeting the PA-PB1 Protein-Protein Interaction: Structure-Activity Relationships Exploration with the Aid of Molecular Modeling. J Med Chem 2016; 59:2688-703. [PMID: 26924568 DOI: 10.1021/acs.jmedchem.5b01935] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Influenza is an infectious disease that represents an important public health burden, with high impact on the global morbidity, mortality, and economy. The poor protection and the need of annual updating of the anti-influenza vaccine, added to the rapid emergence of viral strains resistant to current therapy make the need for antiviral drugs with novel mechanisms of action compelling. In this regard, the viral RNA polymerase is an attractive target that allows the design of selective compounds with reduced risk of resistance. In previous studies we showed that the inhibition of the polymerase acidic protein-basic protein 1 (PA-PB1) interaction is a promising strategy for the development of anti-influenza agents. Starting from the previously identified 3-cyano-4,6-diphenyl-pyridines, we chemically modified this scaffold and explored its structure-activity relationships. Noncytotoxic compounds with both the ability of disrupting the PA-PB1 interaction and antiviral activity were identified, and their mechanism of target binding was clarified with molecular modeling simulations.
Collapse
Affiliation(s)
- Iuni M L Trist
- Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena , Via A. Moro, I-53100 Siena, Italy
| | - Giulio Nannetti
- Dipartimento di Medicina Molecolare, Università degli Studi di Padova , Via A. Gabelli 63, I-35121 Padova, Italy
| | - Cristina Tintori
- Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena , Via A. Moro, I-53100 Siena, Italy
| | - Anna Lucia Fallacara
- Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena , Via A. Moro, I-53100 Siena, Italy
| | - Davide Deodato
- Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena , Via A. Moro, I-53100 Siena, Italy
| | - Beatrice Mercorelli
- Dipartimento di Medicina Molecolare, Università degli Studi di Padova , Via A. Gabelli 63, I-35121 Padova, Italy
| | - Giorgio Palù
- Dipartimento di Medicina Molecolare, Università degli Studi di Padova , Via A. Gabelli 63, I-35121 Padova, Italy
| | - Maikel Wijtmans
- Division of Medicinal Chemistry, Amsterdam Institute for Molecules, Medicines and Systems, VU University Amsterdam , De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands
| | - Tzveta Gospodova
- Institute of Organic Chemistry with Centre of Phytochemistry, Bulgarian Academy of Sciences , Acad. Georgy Bonchev str. BI. 9, 1113 Sofia, Bulgaria
| | - Ewald Edink
- Division of Medicinal Chemistry, Amsterdam Institute for Molecules, Medicines and Systems, VU University Amsterdam , De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands
| | - Mark Verheij
- Division of Medicinal Chemistry, Amsterdam Institute for Molecules, Medicines and Systems, VU University Amsterdam , De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands
| | - Iwan de Esch
- Division of Medicinal Chemistry, Amsterdam Institute for Molecules, Medicines and Systems, VU University Amsterdam , De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands
| | - Lilia Viteva
- Institute of Organic Chemistry with Centre of Phytochemistry, Bulgarian Academy of Sciences , Acad. Georgy Bonchev str. BI. 9, 1113 Sofia, Bulgaria
| | - Arianna Loregian
- Dipartimento di Medicina Molecolare, Università degli Studi di Padova , Via A. Gabelli 63, I-35121 Padova, Italy
| | - Maurizio Botta
- Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena , Via A. Moro, I-53100 Siena, Italy.,Sbarro Institute for Cancer Research and Molecular Medicine, Temple University , BioLife Science Building, Suite 333, 1900 N 12th Street, Philadelphia, Pennsylvania 19122, United States
| |
Collapse
|
12
|
Mercorelli B, Luganini A, Nannetti G, Tabarrini O, Palù G, Gribaudo G, Loregian A. Drug Repurposing Approach Identifies Inhibitors of the Prototypic Viral Transcription Factor IE2 that Block Human Cytomegalovirus Replication. Cell Chem Biol 2016; 23:340-51. [DOI: 10.1016/j.chembiol.2015.12.012] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2015] [Revised: 11/10/2015] [Accepted: 12/04/2015] [Indexed: 11/24/2022]
|
13
|
Massari S, Nannetti G, Desantis J, Muratore G, Sabatini S, Manfroni G, Mercorelli B, Cecchetti V, Palù G, Cruciani G, Loregian A, Goracci L, Tabarrini O. A Broad Anti-influenza Hybrid Small Molecule That Potently Disrupts the Interaction of Polymerase Acidic Protein–Basic Protein 1 (PA-PB1) Subunits. J Med Chem 2015; 58:3830-42. [DOI: 10.1021/acs.jmedchem.5b00012] [Citation(s) in RCA: 70] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Affiliation(s)
- Serena Massari
- Department
of Pharmaceutical Sciences, University of Perugia, 06123 Perugia, Italy
| | - Giulio Nannetti
- Department
of Molecular Medicine, University of Padua, 35121 Padua, Italy
| | - Jenny Desantis
- Department
of Pharmaceutical Sciences, University of Perugia, 06123 Perugia, Italy
| | - Giulia Muratore
- Department
of Molecular Medicine, University of Padua, 35121 Padua, Italy
| | - Stefano Sabatini
- Department
of Pharmaceutical Sciences, University of Perugia, 06123 Perugia, Italy
| | - Giuseppe Manfroni
- Department
of Pharmaceutical Sciences, University of Perugia, 06123 Perugia, Italy
| | | | - Violetta Cecchetti
- Department
of Pharmaceutical Sciences, University of Perugia, 06123 Perugia, Italy
| | - Giorgio Palù
- Department
of Molecular Medicine, University of Padua, 35121 Padua, Italy
| | - Gabriele Cruciani
- Department
of Chemistry, Biology and Biotechnology, University of Perugia, 06123 Perugia, Italy
| | - Arianna Loregian
- Department
of Molecular Medicine, University of Padua, 35121 Padua, Italy
| | - Laura Goracci
- Department
of Chemistry, Biology and Biotechnology, University of Perugia, 06123 Perugia, Italy
| | - Oriana Tabarrini
- Department
of Pharmaceutical Sciences, University of Perugia, 06123 Perugia, Italy
| |
Collapse
|
14
|
Lepri S, Nannetti G, Muratore G, Cruciani G, Ruzziconi R, Mercorelli B, Palù G, Loregian A, Goracci L. Optimization of Small-Molecule Inhibitors of Influenza Virus Polymerase: From Thiophene-3-Carboxamide to Polyamido Scaffolds. J Med Chem 2014; 57:4337-50. [DOI: 10.1021/jm500300r] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Susan Lepri
- Department
of Chemistry, Biology and Biotechnology, University of Perugia, 06123 Perugia, Italy
| | - Giulio Nannetti
- Department
of Molecular Medicine, University of Padua, 35121 Padua, Italy
| | - Giulia Muratore
- Department
of Molecular Medicine, University of Padua, 35121 Padua, Italy
| | - Gabriele Cruciani
- Department
of Chemistry, Biology and Biotechnology, University of Perugia, 06123 Perugia, Italy
| | - Renzo Ruzziconi
- Department
of Chemistry, Biology and Biotechnology, University of Perugia, 06123 Perugia, Italy
| | | | - Giorgio Palù
- Department
of Molecular Medicine, University of Padua, 35121 Padua, Italy
| | - Arianna Loregian
- Department
of Molecular Medicine, University of Padua, 35121 Padua, Italy
| | - Laura Goracci
- Department
of Chemistry, Biology and Biotechnology, University of Perugia, 06123 Perugia, Italy
| |
Collapse
|
15
|
Loregian A, Mercorelli B, Nannetti G, Compagnin C, Palù G. Antiviral strategies against influenza virus: towards new therapeutic approaches. Cell Mol Life Sci 2014; 71:3659-83. [PMID: 24699705 DOI: 10.1007/s00018-014-1615-2] [Citation(s) in RCA: 124] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2013] [Revised: 03/04/2014] [Accepted: 03/18/2014] [Indexed: 01/02/2023]
Abstract
Influenza viruses are major human pathogens responsible for respiratory diseases affecting millions of people worldwide and characterized by high morbidity and significant mortality. Influenza infections can be controlled by vaccination and antiviral drugs. However, vaccines need annual updating and give limited protection. Only two classes of drugs are currently approved for the treatment of influenza: M2 ion channel blockers and neuraminidase inhibitors. However, they are often associated with limited efficacy and adverse side effects. In addition, the currently available drugs suffer from rapid and extensive emergence of drug resistance. All this highlights the urgent need for developing new antiviral strategies with novel mechanisms of action and with reduced drug resistance potential. Several new classes of antiviral agents targeting viral replication mechanisms or cellular proteins/processes are under development. This review gives an overview of novel strategies targeting the virus and/or the host cell for counteracting influenza virus infection.
Collapse
Affiliation(s)
- Arianna Loregian
- Department of Molecular Medicine, University of Padua, via Gabelli 63, 35121, Padua, Italy,
| | | | | | | | | |
Collapse
|
16
|
Massari S, Nannetti G, Goracci L, Sancineto L, Muratore G, Sabatini S, Manfroni G, Mercorelli B, Cecchetti V, Facchini M, Palù G, Cruciani G, Loregian A, Tabarrini O. Structural Investigation of Cycloheptathiophene-3-carboxamide Derivatives Targeting Influenza Virus Polymerase Assembly. J Med Chem 2013; 56:10118-31. [DOI: 10.1021/jm401560v] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Affiliation(s)
- Serena Massari
- Department of Chemistry and Technology
of Drugs, University of Perugia, 06123 Perugia, Italy
| | - Giulio Nannetti
- Department of Molecular Medicine, University of Padua, 35121 Padua, Italy
| | - Laura Goracci
- Department
of Chemistry, Biology, and Biotechnology, University of Perugia, 06123 Perugia, Italy
| | - Luca Sancineto
- Department of Chemistry and Technology
of Drugs, University of Perugia, 06123 Perugia, Italy
| | - Giulia Muratore
- Department of Molecular Medicine, University of Padua, 35121 Padua, Italy
| | - Stefano Sabatini
- Department of Chemistry and Technology
of Drugs, University of Perugia, 06123 Perugia, Italy
| | - Giuseppe Manfroni
- Department of Chemistry and Technology
of Drugs, University of Perugia, 06123 Perugia, Italy
| | | | - Violetta Cecchetti
- Department of Chemistry and Technology
of Drugs, University of Perugia, 06123 Perugia, Italy
| | - Marzia Facchini
- Department of Infectious, Parasitic, and Immunomediated Diseases,
WHO National Influenza Centre, Istituto Superiore di Sanità (ISS), Rome, Italy
| | - Giorgio Palù
- Department of Molecular Medicine, University of Padua, 35121 Padua, Italy
| | - Gabriele Cruciani
- Department
of Chemistry, Biology, and Biotechnology, University of Perugia, 06123 Perugia, Italy
| | - Arianna Loregian
- Department of Molecular Medicine, University of Padua, 35121 Padua, Italy
| | - Oriana Tabarrini
- Department of Chemistry and Technology
of Drugs, University of Perugia, 06123 Perugia, Italy
| |
Collapse
|
17
|
Saladini F, Foley BT, Rosi A, Vicenti I, Nannetti G, Meini G, Razzolini F, Zazzi M. Near full-length sequence analysis of HIV type 1 BF recombinants from Italy. AIDS Res Hum Retroviruses 2012; 28:299-303. [PMID: 21740272 DOI: 10.1089/aid.2011.0002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Recombination between HIV-1 subtypes B and F has generated several circulating and unique recombinant forms, particularly in Latin American areas. In Italy, subtype B is highly prevalent while subtype F is the most common pure non-B subtype. To investigate the recombination pattern in Italian BF recombinant viruses, we characterized full-length sequences derived from 15 adult patients, mostly Italian and infected by the heterosexual route. One of the BF mosaics was a CRF29, three sequences clustered with low bootstrap values with CRF39, CRF40, and CRF42. With the exception of the CRF29-like sequence, the other recombination patterns were unique, but two possible clusters were identified. Analysis of the gp120 V3 domain suggested a possible link with subtype F from Eastern Europe rather than from Latin America, favoring the hypothesis of local recombination between clade B and F viruses over that of import of BF recombinants from Latin America. HIV-1 subtypes B and F appear prone to generation of unique recombinants in Italy, warranting epidemiological surveillance and investigation of a possible clinical significance.
Collapse
Affiliation(s)
- Francesco Saladini
- Section of Microbiology, Department of Biotechnology, University of Siena, Siena, Italy
| | - Brian T. Foley
- HIV Databases, T-6, Los Alamos National Laboratory, Los Alamos, New Mexico
| | - Andrea Rosi
- Section of Microbiology, Department of Biotechnology, University of Siena, Siena, Italy
| | - Ilaria Vicenti
- Section of Microbiology, Department of Biotechnology, University of Siena, Siena, Italy
| | - Giulio Nannetti
- Section of Microbiology, Department of Biotechnology, University of Siena, Siena, Italy
| | - Genny Meini
- Section of Microbiology, Department of Biotechnology, University of Siena, Siena, Italy
| | - Francesca Razzolini
- Section of Microbiology, Department of Biotechnology, University of Siena, Siena, Italy
| | - Maurizio Zazzi
- Section of Microbiology, Department of Biotechnology, University of Siena, Siena, Italy
| |
Collapse
|
18
|
Magi A, Benelli M, Marseglia G, Nannetti G, Scordo MR, Torricelli F. A shifting level model algorithm that identifies aberrations in array-CGH data. Biostatistics 2009; 11:265-80. [DOI: 10.1093/biostatistics/kxp051] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
19
|
Mariotti E, Ruelle A, Nannetti G, Boccardo M. Radiation induced meningioma. A case report. Acta Neurol (Napoli) 1986; 8:145-9. [PMID: 3716900] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
20
|
Gaiani R, Chiesa F, Mattioli M, Nannetti G, Galeati G. Androstenedione and testosterone concentrations in plasma and milk of the cow throughout pregnancy. J Reprod Fertil 1984; 70:55-9. [PMID: 6694152 DOI: 10.1530/jrf.0.0700055] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Androstenedione concentrations in both plasma and milk were higher than those of testosterone throughout pregnancy. Testosterone concentration increased during pregnancy; the levels in milk were always lower than in plasma. Androstenedione concentrations increased in plasma and milk during pregnancy but the values were twice as high in milk as in plasma after Day 90. This change in androstenedione distribution suggests that the mammary gland could be active in the uptake of androstenedione from plasma to milk or that the mammary gland itself might synthesize this hormone.
Collapse
|
21
|
Marcacci G, Nannetti G, Mariotti E. Problems of treatment in the neurological complications of Vaquez disease. Ital J Neurol Sci 1983; 4:319-21. [PMID: 6642998 DOI: 10.1007/bf02043485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
A critical review of the therapeutic measures available to neurologists in a Vaquez disease emergency in the light of the physiopathology of the disease and its complications.
Collapse
|